Citius Oncology Stock Soars 10% on LYMPHIR™ Launch Anticipation

Citius Oncology's stock surged 10% in pre-market trading on June 24, 2025, driven by anticipation of the commercial launch of its FDA-approved cancer drug, LYMPHIR™, in the second half of the year.

Citius Oncology is gearing up for the U.S. commercial launch of LYMPHIR™, an immunotherapy targeting lymphoma. The company estimates significant revenue from this launch, which is expected to bolster its market position and financial performance.

Citius Oncology's stock has seen volatility in recent weeks, with a notable drop of 16.35% on June 23, 2025. However, the upcoming commercial launch of LYMPHIR™ has provided a boost to investor confidence, leading to the recent pre-market surge.